Nexthera Capital as of Sept. 30, 2016
Portfolio Holdings for Nexthera Capital
Nexthera Capital holds 33 positions in its portfolio as reported in the September 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Spdr S&p Oil & Gas Exp & Pr put | 16.3 | $27M | 400k | 66.29 | |
| Pfizer (PFE) | 13.6 | $22M | 654k | 33.87 | |
| GlaxoSmithKline | 9.1 | $15M | 345k | 43.13 | |
| Shire | 8.0 | $13M | 67k | 193.87 | |
| Astrazeneca Plc option | 5.0 | $8.2M | 250k | 32.86 | |
| Acceleron Pharma | 4.8 | $7.9M | 218k | 36.19 | |
| Seattle Genetics | 3.7 | $6.0M | 112k | 54.01 | |
| Insmed (INSM) | 2.9 | $4.7M | 322k | 14.52 | |
| Adamas Pharmaceuticals | 2.8 | $4.6M | 279k | 16.41 | |
| Aquinox Pharmaceuticals | 2.8 | $4.5M | 340k | 13.36 | |
| Lannett Company | 2.7 | $4.4M | 167k | 26.57 | |
| Clovis Oncology | 2.7 | $4.3M | 120k | 36.05 | |
| Immunomedics | 2.5 | $4.1M | 1.3M | 3.25 | |
| Colucid Pharmaceuticals | 2.3 | $3.8M | 100k | 38.15 | |
| Eiger Biopharmaceuticals | 2.2 | $3.5M | 264k | 13.39 | |
| Zogenix | 1.8 | $3.0M | 260k | 11.43 | |
| Ascendis Pharma A S (ASND) | 1.8 | $2.9M | 146k | 20.10 | |
| Fibrogen (FGEN) | 1.6 | $2.6M | 128k | 20.70 | |
| Neuroderm Ltd F | 1.5 | $2.4M | 131k | 18.49 | |
| Immune Design | 1.4 | $2.3M | 305k | 7.58 | |
| Progenics Pharmaceuticals | 1.4 | $2.2M | 350k | 6.33 | |
| Advaxis | 1.3 | $2.1M | 200k | 10.69 | |
| Trevena | 1.2 | $2.0M | 299k | 6.75 | |
| Abeona Therapeutics | 1.2 | $1.9M | 322k | 6.00 | |
| Aerie Pharmaceuticals | 1.2 | $1.9M | 50k | 37.74 | |
| Concert Pharmaceuticals I equity | 1.0 | $1.7M | 168k | 10.11 | |
| Axovant Sciences | 0.9 | $1.4M | 100k | 14.00 | |
| Foamix Pharmaceuticals | 0.7 | $1.2M | 125k | 9.26 | |
| Ophthotech | 0.7 | $1.1M | 24k | 46.12 | |
| Vistagen Therapeutics | 0.3 | $575k | 138k | 4.16 | |
| Verastem | 0.3 | $447k | 336k | 1.33 | |
| Vascular Biogenics | 0.1 | $174k | 33k | 5.22 | |
| Biopharmx | 0.0 | $32k | 58k | 0.56 |
